Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
Open accessThe DOI matches its Crossref record; 83 of the 87 references it cites were found in a registry or an index; 53 of the 80 sources its claims cite were checked for support.
Abstract
The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a relatively new class of antidiabetic drugs that act by mimicking the function of endogenous glucagon-like peptide 1. They constitute valuable agents for the management of T2DM as, in addition to exerting a strong hypoglycemic action, they present cardiorenal protective properties, promote weight loss, and have a good safety profile, particularly with respect to the risk of hypoglycemia. Due to the precedent of studies having identified sexual dimorphic elements regarding the action of other antidiabetic agents, ongoing research has attempted to examine whether this is also the case for GLP-1 RAs. Until now, sex differences have been observed in the impact of GLP1-RAs on glycemic control, weight reduction, and frequency of adverse events. On the contrary, the question of whether these drugs differentially affect the two sexes with respect to cardiovascular risk and incidence of major adverse cardiovascular events remains under investigation. Knowledge of the potential sex-specific effects of these medications is extremely useful for the implementation of individualized therapeutic plans in the treatment of T2DM. This narrative review aims to present the available data regarding the sex-specific action of GLP-1 RAs as well as to discuss the potential pathophysiologic mechanisms explaining these dissimilarities.
Overview
CoChat Summary
TL;DR
This narrative review examines whether biological sex modifies the efficacy and safety of GLP-1 receptor agonists in type 2 diabetes and obesity. It concludes that women tend to achieve greater weight loss and report more gastrointestinal adverse events, while sex differences in glycemic control and cardiovascular outcomes remain inconsistent and under-investigated.
Key findings
- Weight loss appears more pronounced in women across several studies: e.g., −7.0 kg vs. −3.3 kg in a retrospective study (p < 0.06); 33% of women vs. 17% of men achieved weight-loss targets after 12 months of exenatide; BMI reduction 4.8 vs. 2.6 kg/m² (p < 0.05); dulaglutide −1.32 kg in females (p = 0.001) vs. +0.09 kg in males (p < 0.001). Liraglutide exposure was 32% higher in women than men of comparable weight.
- Glycemic efficacy findings are mixed. Some analyses show no sex effect (dulaglutide HbA1c reduction −1.26% in men vs. −1.33% in women; post hoc analysis of 855 patients), while others favor women (exenatide plus metformin reduced HbA1c from 8.8% to 6.8% in women vs. 8.9% to 7.5% in men, p < 0.05; metformin plus liraglutide −1.5 vs. −0.75, p = 0.028) or men (38% vs. 27% achieved HbA1c ≤7% with exenatide twice daily, p = 0.03; male sex predicted treatment failure, OR 2.55).
- Women report more adverse events, especially gastrointestinal: dulaglutide 86.5% of women vs. 61.4% of men; liraglutide 83.3% vs. 65.5%. A Korean database analysis found women about twice as likely to report any adverse event (reporting ratio 2.34) and higher headache risk (risk ratio 7.97). No significant sex difference was found for nocturnal or total hypoglycemia.
- Cardiovascular and MACE findings are inconclusive: some studies show no sex divergence (hazard ratio 0.88 in both sexes; meta-analysis p = 0.375), while one study found lower MACE incidence in women (6.6 vs. 11.9 per 1000 person-years, p < 0.001) and a greater risk reduction with GLP-1 RAs vs. sulfonylureas in women (adjusted HR 0.57 vs. 0.82, p = 0.001). Effects on waist circumference, blood pressure, and lipids remain uncertain.
Methods
- Design: narrative review of available data on sex-specific actions of GLP-1 RAs in type 2 diabetes and obesity.
- Data: synthesized evidence from clinical trials, pooled and post hoc analyses, retrospective and cohort studies, meta-analyses, pharmacokinetic/exposure analyses, and animal studies.
- Analysis: narrative synthesis, with tables summarizing drug characteristics, exposure/dose–effectiveness–adverse event relationships, and sex differences. No systematic search strategy or meta-analysis is described.
Limitations
- Stated by the authors: most referenced studies have heterogeneous patient populations differing in diabetes duration, pharmacologic regimen, and prior medication history; most studies examining sex effects are post hoc analyses with secondary outcomes; and many studies lack sex-disaggregated data.
- Evident from the text: as a narrative review, it does not describe a systematic search, quality appraisal, or quantitative synthesis; findings across studies are conflicting, and only a small number of studies stratified cardiovascular outcomes by sex.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
49 Valid · 6 Not valid · 21 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In male mice, specific upregulated DEGs were associated with mitochondrial function, which is known to affect the process of insulin secretion.”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 5. Discussion
What the sources say
- Disputedcites [84] Liu, 2021, Single-cell RNA Sequencing Reveals Sexually Dimorphic Transcriptome and Type 2 Diabetes Genes in Mouse Islet β Cells, Genom. Proteom. Bioinform. sourceExperimental — accuracy not yet measured
In Results (‘Extensive sex-dependent T2D gene expression alterations in mouse β cells’; page unavailable), the paper identifies the mitochondrial-function genes Cox4i1 and Ndufb7 as down-regulated in β cells of male T2D mice, contrary to the claim that they were upregulated. The same passage does associate mitochondrial function with insulin secretion capacity. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The pathophysiology of these sex-specific differences is to a great extent hormonally regulated, with estrogen playing a key role in the disease process in females [13].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 1. Introduction
What the sources say
- Partly supportedcites [13] Arnetz, 2014, Sex differences in type 2 diabetes: Focus on disease course and outcomes, Diabetes Metab. Syndr. Obes. Targets Ther. sourceExperimental — accuracy not yet measured
The sections on hormonal pathophysiology and estrogen describe sex-related hormonal effects on glycemic control, including an association between declining estrogen after menopause and increased risk of elevated fasting plasma glucose. But the Introduction says the reasons for sex differences remain unclear and lists other possible contributors; the paper does not establish that they are to a great extent hormonally regulated. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies that used different representatives of the class, such as dulaglutide and liraglutide, have generated similar findings [50,57].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.2. Weight Loss
What the sources say
- Supportedcites [50] Gallwitz, 2018, Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c, Diabetes Obes. Metab. source
For the dulaglutide part of the multi-citation sentence, the Discussion reports that women had numerically greater weight loss or less weight gain than men in the majority of studies. The paper does not establish a statistically significant sex difference in weight loss. (LLM, conf=0.88)
- Supportedcites [57] Onishi, 2017, Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan, Endocr. J. source
The Efficacy section reports numerically greater weight loss in females than males treated with either dulaglutide or liraglutide in the analyzed Japanese patients with type 2 diabetes. The Discussion likewise states that females treated with both drugs had greater mean weight loss. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Due to the relatively recent authorization for clinical use for the treatment of T2DM, the sex-specific properties of these agents have not been adequately investigated [21,22].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [21] Pencek, 2012, Exenatide Twice Daily: Analysis of Effectiveness and Safety Data Stratified by Age, Sex, Race, Duration of Diabetes, and Body Mass Index, Postgrad. Med. source
- Supportedcites [22] Anichini, 2013, Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: A real world experience, Diabetes Metab. Syndr. Obes. source
The Introduction says data on gender differences in routine exenatide use are scarce. The Discussion adds that few clinical studies have specifically investigated gender differences in therapy with GLP-1 receptor agonists, supporting the claim that their sex-specific clinical effects remain insufficiently studied. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similar results were presented in another cohort study in which after a 12-month period of exenatide treatment, 33% of women achieved weight loss targets compared to 17% of men [22].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.2. Weight Loss
What the sources say
- Supportedcites [22] Anichini, 2013, Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: A real world experience, Diabetes Metab. Syndr. Obes. source
The Results report that at 12 months, 33% of women versus 17% of men achieved the study’s target weight loss. Patients and methods describes a cohort treated with exenatide and followed for 12 months. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims · 27 with their cited sources checked
Create a free account to see all 103 claims and to verify the 3 references still open.
- It may state two separate claims as one. 35
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adverse effects also differ: women report higher rates of gastrointestinal intolerance (nausea, vomiting, cholelithiasis) with incretin-based therapies, likely due to estrogen’s effects on biliary motility [182].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Given that GI AEs occur more commonly in females than in males, the sex-related differences in GI AEs may offer an additional framework to explain the increased efficacy of these drugs among women, independently from the level of exposure ([76]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Given that GI AEs occur more commonly in females than in males, the sex-related differences in GI AEs may offer an additional framework to explain the increased efficacy of these drugs among women, independently from the level of exposure ([76]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Obesity and T2D are characterized by sexual dimorphism, which appears to be an important determinant of presentation, diagnosis, disease progression and complications, and, therefore, may be important for individual treatment approaches ([76,77,78]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Although the different GLP-1 RAs do not allow the same results to be achieved in terms of weight loss, cumulative evidence suggests that, even by using different representatives of this class, weight reduction is similarly more pronounced in females than in males ([76]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.1. Hypoglycemic Efficacy
“HbA1c target (≤7% or 53 mmol/mL)”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.1. Hypoglycemic Efficacy
“HbA1c levels < 7% (<53 mmol/mol)”
Citations
Cites
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
The Pathophysiology of Gestational Diabetes Mellitus
Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113342 · Cited by 1,874 · cited 1×
“However, in an individual with pre-existing β-cell dysfunction this process of adaptation is not possible and therefore a hyperglycemic state occurs [19].”
BackgroundThe role of estrogens in control of energy balance and glucose homeostasis
Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1055 · Cited by 1,329
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Direct effects of sex steroid hormones on adipose tissues and obesity
Mayes, J. S., & Watson, G. H. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00152.x · Cited by 508
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388
Gender differences in glucose homeostasis and diabetes
Mauvais-Jarvis, F. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.08.016 · Cited by 377 · cited 2×
“More specifically, it has been argued that testosterone deficiency may be responsible for insulin resistance in males, whereas in females the latter can occur as a result of a hyperandrogenic state [14].”
BackgroundTakahashi, T. A., & Johnson, K. M. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.01.006 · Cited by 355
Effects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Targeted estrogen delivery reverses the metabolic syndrome
Finan, B., Yang, B., Ottaway, N., Stemmer, K., Müller, T. D., Yi, C.-X., Habegger, K., Schriever, S. C., García-Cáceres, C., Kabra, D. G., et al. (2012) · Nature Medicine · doi:10.1038/nm.3009 · Cited by 337
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Hall, E., Volkov, P., Dayeh, T., Esguerra, J. L. S., Salö, S., Eliasson, L., Rönn, T., Bacos, K., & Ling, C. (2014) · Genome Biology · doi:10.1186/s13059-014-0522-z · Cited by 249 · cited 1×
“Increased methylation of a gene’s promoter is known to induce gene silencing [82], and thus increased methylation of the DUSP9 gene could act as a risk factor for insulin resistance and T2DM [83].”
BackgroundNauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232 · cited 1×
“Aside from their previously mentioned benefits, GLP-1 RAs exert several other favorable effects such as the decrease of waist circumference (WC) [60] and blood pressure (BP) [61], as well as the modification of various elements of the lipid profile, thus resulting in reduced CVD risk [62].”
BackgroundWang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198
Is HbA1c an ideal biomarker of well-controlled diabetes?
Kaiafa, G. D., Veneti, S., Polychronopoulos, G., Pilalas, D., Daios, S., Kanellos, I., Didangelos, T., Pagoni, S., & Savopoulos, C. G. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138756 · Cited by 182
Sex differences in type 2 diabetes: focus on disease course and outcomes
Arnetz, L., Rajamand Ekberg, N., & Alvarsson, M. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s51301 · Cited by 175 · cited 2×
“The pathophysiology of these sex-specific differences is to a great extent hormonally regulated, with estrogen playing a key role in the disease process in females [13].”
BackgroundMenstrual cycle and voluntary food intake
Gong, E. J., Garrel, D., & Calloway, D. H. (1989) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/49.2.252 · Cited by 163
Kalish, G. M., Barrett-Connor, E., Laughlin, G. A., & Gulanski, B. I. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021375 · Cited by 156
Sex differences underlying pancreatic islet biology and its dysfunction
Gannon, M., Kulkarni, R. N., Tse, H. M., & Mauvais-Jarvis, F. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.017 · Cited by 133 · cited 1×
“Increased methylation of a gene’s promoter is known to induce gene silencing [82], and thus increased methylation of the DUSP9 gene could act as a risk factor for insulin resistance and T2DM [83].”
BackgroundMarbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126
Geiser, J. S., Heathman, M. A., Cui, X., Martin, J. A., Loghin, C., Chien, J. Y., & de la Peña, A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0338-3 · Cited by 126
Singh, A. K., & Singh, R. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.02.012 · Cited by 114 · cited 1×
“Studies that examined the efficacy of GLP-1 RA with respect to cardiovascular outcomes noted a remarkable reduction in MACE in both sexes [67,68], although without apparent sex-related divergence (hazard ratio of MACE occurrence 0.”
BackgroundRoche, M. M., & Wang, P. P. (2013) · Diabetes Care · doi:10.2337/dc12-1272 · Cited by 113 · cited 1×
“They also face a higher all-cause mortality and a higher CVD-related morbidity and mortality [16].”
BackgroundRyan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.05.009 · Cited by 111
Raparelli, V., Elharram, M., Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., & Pilote, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012940 · Cited by 106 · cited 2×
“001), further suggesting a two-way drug-by-sex interaction [70].”
BackgroundGLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2021) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 103
Sex and estrogens alter the action of glucagon-like peptide-1 on reward
Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102 · cited 1×
“In this sense, higher estrogen concentrations in females, especially during their premenopausal years, could potentially serve as an explanation for why women may respond better to GLP-1 RAs [85].”
BackgroundExposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12639 · Cited by 102
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98 · cited 2×
“Studies that used different representatives of the class, such as dulaglutide and liraglutide, have generated similar findings [50,57].”
BackgroundResultAdiponectin serum levels correlate with insulin resistance in type 2 diabetic patients
Aleidi, S. M., Issa, A., Bustanji, H., Khalil, M., & Bustanji, Y. K. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2014.11.011 · Cited by 97
Vogel, H., Wolf, S., Rabasa, C., Rodriguez-Pacheco, F., Babaei, C. S., Stöber, F., Goldschmidt, J., DiMarchi, R. D., Finan, B., Tschöp, M. H., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.039 · Cited by 86 · cited 1×
“This activation results in a greater modification of the food-reward behavior and therefore can potentially lead to a greater reduction in body weight [88].”
BackgroundCastellana, M., Cignarelli, A., Brescia, F., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-55524-w · Cited by 86
Chiu, C.-J., & Wray, L. A. (2011) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9226-0 · Cited by 84 · cited 1×
“Cumulative evidence suggests that females with T2DM exhibit inferior glycemic control and are less likely to achieve their HbA1c targets [15].”
BackgroundDamholt, B., Golor, G., Wierich, W., Pedersen, P., Ekblom, M., & Zdravkovic, M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288215 · Cited by 82
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity
Pasquali, R., Vicennati, V, Gambineri, A., & Pagotto, U. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.129 · Cited by 74 · cited 1×
“More specifically, 70% of women with T2D present with abdominal obesity, whereas the corresponding percentage for men with T2D is approximately 40% [12].”
BackgroundPoudel, I., Tejpal, C., Rashid, H., & Jahan, N. (2019) · Cureus · doi:10.7759/cureus.5280 · Cited by 71
Buysschaert, M., Preumont, V., Oriot, P. R., Paris, I., Ponchon, M., Scarnière, D., & Selvais, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.009 · Cited by 68
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Quan, H., Zhang, H., Wei, W., & Fang, T. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.013 · Cited by 65
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0410-7 · Cited by 64
Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro
Root-Bernstein, R., Podufaly, A., & Dillon, P. F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00118 · Cited by 63
Seghieri, G., Anichini, Cosimi, S., Carlo, D., Bellis, D., Franconi, Orsini, P., & Baccetti (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s42729 · Cited by 63 · cited 2×
“Due to the relatively recent authorization for clinical use for the treatment of T2DM, the sex-specific properties of these agents have not been adequately investigated [21,22].”
BackgroundResultHausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0532-6 · Cited by 62
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010207 · Cited by 61 · cited 1×
“It should be noted that in this particular case, the female participants were slightly heavier than the males at the beginning of the study [58].”
BackgroundGender differences in adverse event reports associated with antidiabetic drugs
Joung, K.-I., Jung, G.-W., Park, H.-H., Lee, H., Park, S.-H., & Shin, J.-Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-74000-4 · Cited by 61
Effect of gender on treatment outcomes in type 2 diabetes mellitus
McGill, J. B., Vlajnic, A., Knutsen, P. G., Recklein, C., Rimler, M., & Fisher, S. J. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.10.001 · Cited by 61
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53 · cited 2×
“) [73] Exposure–Response Analyses of Liraglutide (J.”
ResultPencek, R., Blickensderfer, A., Li, Y., Brunell, S. C., & Anderson, P. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2567 · Cited by 52 · cited 6×
“However, according to this analysis, low-density lipoprotein cholesterol (LDL-C) did not decrease in women, indicating the presence of a specific sex effect of exenatide on lipid profiles [21].”
BackgroundResultInfluentialBray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0321-6 · Cited by 47
Onishi, Y., Oura, T., Matsui, A., Matsuura, J., & Iwamoto, N. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0552 · Cited by 47 · cited 5×
“Studies that used different representatives of the class, such as dulaglutide and liraglutide, have generated similar findings [50,57].”
BackgroundResultInfluentialD’Andrea, E., Kesselheim, A. S., Franklin, J. M., Jung, E. H., Hey, S. P., & Patorno, E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01133-1 · Cited by 45
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.
Smith, L. L., Mosley, J., Parke, C. K., Brown, J., Ls, B., & Phan, L. D. (2016) · PubMed Central · Cited by 43
Calcitonin as a biomarker of C cell disease: recent achievements and current challenges
Costante, G., & Meringolo, D. (2020) · Endocrine · doi:10.1007/s12020-019-02183-6 · Cited by 41
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Marchese, E., Rodeghier, C., Monson, R. S., McCracken, B., Shi, T., Schrock, W., Martellotto, J., Oberholzer, J., & Danielson, K. K. (2015) · Diabetes Care · doi:10.2337/dc15-0723 · Cited by 41 · cited 1×
“More specifically, according to a study conducted on biopsies of human pancreases, the percentage of β-cells in the female pancreatic islets appeared to exceed that of the male islets (6% more β-cells on average in females) [81].”
BackgroundNathan, B. M., Rudser, K. D., Abuzzahab, M. J., Fox, C. K., Coombes, B. J., Bomberg, E. M., & Kelly, A. S. (2016) · Clinical Obesity · doi:10.1111/cob.12128 · Cited by 39 · cited 1×
“However, these have been observed mainly in animal studies and a cause–effect relationship among GLP-1 Ras, and these outcomes have not been established in human clinical trials [71].”
BackgroundHan, E., Kim, A., Lee, S. J., Kim, J.-Y., Kim, J. H., Lee, W. J., & Lee, B.-W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0470-9 · Cited by 35
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed Central · Cited by 35
Koning, S. H., Lutgers, H. L., Hoogenberg, K., Trompert, C. A., van den Berg, P. P., & Wolffenbuttel, B. H. R. (2016) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-016-0282-2 · Cited by 31
Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes
Onishi, Y., Oura, T., Nishiyama, H., Ohyama, S., Takeuchi, M., & Iwamoto, N. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0518 · Cited by 31 · cited 2×
“This is in agreement with a post hoc analysis of 855 patients undergoing dulaglutide treatment, in which the reduction in HbA1c was once again shown to be unaffected by sex [51].”
BackgroundResultLiu, G., Li, Y., Zhang, T., Li, M., Li, S., He, Q., Liu, S., Xu, M., Xiao, T., Shao, Z., et al. (2021) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2021.07.004 · Cited by 30
Hemmer, A., Maiter, D., Buysschaert, M., & Preumont, V. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.007 · Cited by 29
Fala, L. (2015) · PubMed Central · Cited by 28
Campesi, I., Seghieri, G., & Franconi, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.007 · Cited by 25 · cited 1×
“A case in point is metformin, the first-line treatment drug for T2DM, which produces similar results in terms of glycemic efficacy between the two sexes [79,80].”
ResultDurden, E., Lenhart, G., Lopez-Gonzalez, L., Hammer, M., & Langer, J. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2015.1131703 · Cited by 23
Chiefari, E., Capula, C., Vero, A., Oliverio, R., Puccio, L., Liguori, R., Pullano, V., Greco, M., Foti, D., Tirinato, D., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0412 · Cited by 22 · cited 5×
“However, it may be important to note that the population of this study was reported by the authors to be lacking genetic diversity, which could potentially affect the generalizability of its conclusions [5].”
BackgroundResultInfluentialRisk factors for cardiovascular disease in women with diabetes
Maric, C. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.11.007 · Cited by 17 · cited 1×
“This is of great interest because the population of patients with diabetes manifests a distinct epidemiological composition; as already mentioned above, in contrast to the male predominance observed in the general population as far as cardiovascular events are concerned, in diabetic individuals this risk appears to be…”
ResultLi, J., Li, J., Shan, Z., Yang, W., Liu, J., Tian, H., Zhou, Z., Ji, Q., Weng, J., Jia, W., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0006 · Cited by 16 · cited 1×
“A case in point is metformin, the first-line treatment drug for T2DM, which produces similar results in terms of glycemic efficacy between the two sexes [79,80].”
ResultKoufakis, T., Παπάνας, Ν., Zebekakis, P. E., & Kotsa, K. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1942843 · Cited by 13
Self-citationGastrointestinal safety across the albiglutide development programme
Leiter, L. A., Mallory, J. M., Wilson, T. H., & Reinhardt, R. R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12679 · Cited by 13
Research works printed but not linked: 5
- (2022, February 28). PubChem Exenatide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/45588096.
- (2022, February 28). PubChem Liraglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/16134956.
- (2022, February 28). PubChem Albiglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/145994868.
- (2022, February 28). PubChem Lixisenatide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/90472060.
- (2022, February 28). PubChem Semaglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/56843331.
Cited by
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kim, K. S., Park, J. S., Hwang, E., Park, M. J., Shin, H. Y., Lee, Y. H., Kim, K. M., Gautron, L., Godschall, E., Portillo, B., et al. (2024) · Science · doi:10.1126/science.adj2537 · Cited by 148
Sex-based differences in insulin resistance
Gado, M., Tsaousidou, E., Bornstein, S. R., & Perakakis, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0245 · Cited by 139
Metadata
- Authors
- Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Corresponding author
- Kotsa, Kalliopi
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2022-03-13
- Volume
- 12
- Issue
- 3
- Pages
- 454
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8950819
- OpenAlex
- W4221056231
- Cited by
- 140
- References
- 87
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 40 · 2023: 17 · 2022: 4
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Sex and Gender in Healthcare
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- sex differences, GLP-1 receptor agonists, type 2 diabetes, obesity, glycemic control, weight loss, major adverse cardiovascular events, cardiorenal protection, adverse drug reactions, personalized medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
